Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics Inc (NQ: CGEM )

16.02 +0.44 (+2.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cullinan Therapeutics Inc

< Previous 1 2 3 4 5 Next >
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
From Cullinan Oncology, Inc.
Via GlobeNewswire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
What 4 Analyst Ratings Have To Say About Cullinan Oncology
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Insiders Buy Around $15M Of 2 Stocks
Although the Dow Jones dropped by around 350 points on Friday, there were a few notable insider trades. 
Via Benzinga
Short Volatility Alert: Cullinan Oncology
On Monday, shares of Cullinan Oncology, Inc. (NASDAQ: CGEM) experienced volatile short activity. After the activity, the stock price went up at 2.45% to $10.88. The overall... 
Via Benzinga
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.